Medtronic (MDT) Reports In-Line Q2 EPS; Updates on FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Medtronic (MDT) PT Raised to $83 at Piper Jaffray Following Q2 and Deal Progress
November 19, 2014 8:45 AM ESTPiper Jaffray analyst Brooks West reiterated an Overweight rating and boosted his price target on Medtronic, Inc. (NYSE: MDT) to $83.00 (from $74.00) Wednesday following solid Q2 results and progress on the Covidien deal.
West commented, "
Medtronic reported F2Q15 results with revenues of $4.366B... More



